Treatment Persistence and Compliance with Medications for Chronic Obstructive Pulmonary Disease | Zendy

Joyce A. Cramer | Zendy; Carole Bradley-Kennedy | Zendy; Alissa Scalera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment Persistence and Compliance with Medications for Chronic Obstructive Pulmonary Disease

Author(s) -

Joyce A. Cramer,

Carole Bradley-Kennedy,

Alissa Scalera

Publication year - 2007

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2007/161652

Subject(s) - medicine , salmeterol , ipratropium bromide , ipratropium , formoterol , budesonide/formoterol , copd , tiotropium bromide , asthma , discontinuation , salbutamol , budesonide , persistence (discontinuity) , fluticasone , inhaler , bronchodilator , lung function , geotechnical engineering , lung , engineering

Inhaled beta-agonist, anticholinergic and glucocorticoid medications are used to treat asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the patterns of persistence with the above mentioned inhaled medications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research